Phosphate homeostasis and its role in bone health

Pediatric Nephrology Unit, Clinics Hospital, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Pediatric Nephrology (Impact Factor: 2.88). 05/2012; 27(11):2039-48. DOI: 10.1007/s00467-012-2175-z
Source: PubMed

ABSTRACT Phosphate is one of the most abundant minerals in the body, and its serum levels are regulated by a complex set of processes occurring in the intestine, skeleton, and kidneys. The currently known main regulators of phosphate homeostasis include parathyroid hormone (PTH), calcitriol, and a number of peptides collectively known as the "phosphatonins" of which fibroblast growth factor-23 (FGF-23) has been best defined. Maintenance of extracellular and intracellular phosphate levels within a narrow range is important for many biological processes, including energy metabolism, cell signaling, regulation of protein synthesis, skeletal development, and bone integrity. The presence of adequate amounts of phosphate is critical for the process of apoptosis of mature chondrocytes in the growth plate. Without the presence of this mineral in high enough quantities, chondrocytes will not go into apoptosis, and the normal physiological chain of events that includes invasion of blood vessels and the generation of new bone will be blocked, resulting in rickets and delayed growth. In the rest of the skeleton, hypophosphatemia will result in osteomalacia due to an insufficient formation of hydroxyapatite. This review will address phosphate metabolism and its role in bone health.

Download full-text


Available from: Maria Goretti M G Penido, Aug 14, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Control of systemic inorganic phosphate (Pi) levels is crucial for osteoid mineralization. Parathyroid hormone (PTH) mediates actions on phosphate homeostasis mostly by regulating the activity of the type 2 sodium-phosphate cotransporter (Npt2), and this action requires the PDZ protein NHERF1. Osteoblasts express Npt2 and in response to PTH enhance osteogenesis by increasing mineralized matrix. The regulation of Pi transport in osteoblasts is poorly understood. To address this gap we characterized PTH-dependent Pi transport and the role of NHERF1 in primary mouse calvarial osteoblasts. Under proliferating conditions osteoblasts express Npt2a, Npt2b, PTH receptor, and NHERF1. Npt2a mRNA expression was lower in calvarial osteoblasts from NHERF1-null mice. Under basal conditions Pi uptake in osteoblasts from wild-type mice was greater than that of knockout mice. PTH inhibited Pi uptake in proliferating osteoblasts from wild-type mice, but not in cells from knockout mice. In vitro induction of mineralization enhanced osteoblast differentiation and increased osterix and osteocalcin expression. Contrary to the results with proliferating osteoblasts, PTH increased Pi uptake and ATP secretion in differentiated osteoblasts from wild-type mice. PTH had no effect on Pi uptake or ATP release in differentiated osteoblasts from knockout mice. NHERF1 regulation of PTH-sensitive Pi uptake in proliferating osteoblasts is mediated by cAMP/PKA and PLC/PKC, while modulation of Pi uptake in differentiated osteoblasts depends only on cAMP/PKA signaling. The results suggest that NHERF1 cooperates with PTH in differentiated osteoblasts to increase matrix mineralization. We conclude that NHERF1 regulates PTH that differentially affects Na-dependent Pi transport at distinct stages of osteoblast proliferation and maturation.
    Bone 10/2012; 52(1). DOI:10.1016/j.bone.2012.10.001 · 4.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The common denominator for all types of rickets is hypophosphatemia, leading to inadequate supply of the mineral to the growing bone. Hypophosphatemia can result from insufficient uptake of the mineral from the gut or its disproportionate losses in the kidney, the latter being caused by either tubular abnormalities per se or the effect on the tubule of circulating factors like fibroblast growth factor-23 and parathyroid hormone (PTH). High serum levels of the latter result in most cases from abnormalities in vitamin D metabolism which lead to decreased calcium absorption in the gut and hypocalcemia, triggering PTH secretion. Rickets is a disorder of the growth plate and hence pediatric by definition. However, it is important to recognize that the effect of hypophosphatemia on other parts of the skeleton results in osteomalacia in both children and adults. This review addresses the etiology, pathophysiologic mechanisms, clinical manifestations and treatment of entities associated with hypophosphatemic rickets due to perturbations in renal tubular function.
    Pediatric Nephrology 05/2013; 29(3). DOI:10.1007/s00467-013-2466-z · 2.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context:Pathophysiology of calcium-phosphate disturbances in diabetic kidney disease differs from that in non-diabetic chronic kidney disease (CKD).Objective:We compared the effect of 6-day high-phosphate diet on serum fibroblast growth factor-23 (FGF-23) and other parameters of calcium-phosphate metabolism in diabetic (DM) and non-diabetic CKD patients (non-DM).Design and Setting:Prospective interventional study in research center setting.Participants, Intervention and Measures:26 non-dialysis patients with stages 2-5 CKD and albuminuria < 300 mg/g creatinine were recruited from February 2011 to November 2012 (15 DM, 11 non-DM). All patients received high-phosphate diet (1800 mg/day) for 6 days. At baseline, day 3 and 7 serum FGF-23, parathyroid hormone (PTH), Ca, P, 25OHD, 1,25(OH)2D, MCP-1, and calcium and phosphate urine excretion were measured.Results:In diabetic CKD patients serum calcium was lower on day 3 and 7 vs. baseline, (p<0.01, respectively), in non-DM it was unchanged. Serum phosphorus increased significantly only in non-DM on day 3 and 7 vs. baseline (p<0.01, respectively). Serum PTH was higher in DM group on day 7 vs. baseline (p=0.04). Plasma 25OHD, 1,25(OH)2D and serum MCP-1 were unchanged in both groups. Serum FGF-23 increased in DM from baseline to day 3 (58.1±52.7 and 91.6±71.1 pg/mL, p=0.001), but later tended to decrease. In non-DM there was a steady increase of FGF-23 between baseline and day 7 (75±84.3 to 176±197 pg/mL, p=0.04). Urine phosphate excretion was significantly higher on day 7 in diabetic patients only (p<0.05).Conclusions:PTH seems to play the major role in regulation of phosphate excretion in diabetic CKD. The role of FGF-23 in phosphate disposal in diabetic CKD remains debatable.
    The Journal of Clinical Endocrinology and Metabolism 10/2013; 98(12). DOI:10.1210/jc.2013-2418 · 6.31 Impact Factor
Show more